Locations:
Search
Durvalumab monotherapy appears safe and well-tolerated
Phase I study also reveals possible resistance mechanisms to HER2 antibodies
Encouraging clinical efficacy with no rise in adverse events
Surprising outcome differs from previous results
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Study finds good hematologic response and rapid action
Artificial intelligence applied to clinical and genomic data improves accuracy
Meet the Director of Cleveland Clinic’s new Center for Immunotherapy and Precision Immuno-Oncology
Screening assay effective across all stages, can identify tissue of origin
Leveraging the prognostic significance of sentinel lymph node biopsy histologic patterns
Study finds that even patients with extensive disease benefit from treatment
Advertisement
Advertisement